Diabetes
Current CDC estimate—about 1 in every 8 people in the United States.
BURN INGREDIENT SCIENCE
Five botanicals.
One evidence standard.
Start with Burn’s actual ingredients, then follow each evidence trail from biological mechanism to human ingredient research. Preclinical and ingredient findings are not clinical evidence for the finished Burn formula.
Prediabetes
More than 2 in 5 U.S. adults; most do not know they have it.
Type 2 diabetes
The share of diagnosed diabetes cases classified as type 2.
These figures are public-health context only. They do not show that Burn prevents, treats, or improves diabetes, prediabetes, or any other condition. Population statistics cannot determine your diagnosis, treatment needs, or supplement suitability.
HOW THE SYSTEM WORKS →CDC NATIONAL REPORT ↗DIABETES · PREDIABETES · GLP-1 CARE
Population need meets
personal foundations.
Current CDC estimates report 40.1 million people with diabetes and 115.2 million U.S. adults with prediabetes. Our GLP-1 wellness pathway connects that context to habit support, evidence boundaries, and clinician coordination.
BERBERINE → CELLULAR ENERGY → AMPK
Why AMPK belongs in
Burn’s science story.
Berberine is the connection. It is Burn’s lead metabolic botanical—not a random pathway added beside the product. In cell and animal experiments, berberine has been observed to alter cellular energy handling, increase the AMP-to-ATP ratio, and increase AMPK phosphorylation.
Think of AMPK as a cellular fuel gauge. When energy availability changes, AMPK can help coordinate fuel-use pathways. But the science is not one-dimensional: other experiments found berberine increased glucose consumption even when AMPK signaling was blocked.
Evidence boundary: these are mechanism studies, largely in cells and animals. They do not prove that Burn activates AMPK, lowers blood sugar, builds mitochondria, or causes weight loss in people.
ENERGY STATUSAMP : ATP ↑LOW CELLULAR ENERGY SIGNAL
AMP
αCATALYTICβSCAFFOLDγSENSOR
PThr172
HETEROTRIMERIC ENERGY SENSORAMPK
BURN’S FIVE BOTANICALS · FIVE EVIDENCE TRAILS
Start with the ingredient.
Then inspect the evidence.
Each card starts with a Burn botanical, shows the research context, and keeps the finished-formula boundary visible.
INGREDIENT IDENTITYWhat the botanical is and why it appears in Burn.INGREDIENT RESEARCHWhat a specific substance has been studied to do.PRODUCT CLAIMWhat can responsibly be said about the finished Burn formula.
AMPKCELLULAR ENERGY SENSING
BURN CONNECTION · BERBERINE LEADS
01 · Berberine + AMPK-associated signaling
Berberine is Burn’s lead metabolic botanical. Cell and animal experiments have examined cellular energy handling and AMPK phosphorylation, while human ingredient studies have examined glucose and lipid markers using specific preparations and doses.
Evidence boundary Preclinical mechanism findings do not establish that Burn activates AMPK. Human berberine studies are not clinical trials of Burn and do not prove a disease-treatment or individual result.
N. SATIVATHYMOQUINONE + PATHWAYS
BLACK SEED · NIGELLA SATIVA
02 · Thymoquinone + pathway research
Black Seed contains thymoquinone and other compounds studied across laboratory, animal, review, and human ingredient research involving oxidative-stress, inflammatory, and immune pathways. Preparations, doses, and study quality vary.
Evidence boundary Pathway research does not show that Black Seed—or Burn—boosts immunity, prevents infection, treats inflammatory disease, or produces a defined clinical outcome.
SILSILYMARIN RESEARCH
MILK THISTLE
03 · Silymarin + hepatic context
Milk thistle contains the silymarin complex. Laboratory research has explored antioxidant mechanisms, while clinical research has examined specific silymarin preparations in hepatic contexts.
Evidence boundary This research does not make Burn a “detox,” a treatment for liver disease, or protection against alcohol-related injury. Mechanism and clinical outcome remain distinct.
C. VERUMCEYLON CINNAMON RESEARCH
CEYLON CINNAMON · CINNAMOMUM VERUM
04 · Ceylon cinnamon + glucose-metabolism context
Cinnamon has been examined in human metabolic research, but species, plant parts, preparations, doses, and findings vary. Ceylon cinnamon is botanically distinct from cassia cinnamon.
Evidence boundary Ingredient research does not establish that Burn controls blood sugar, treats diabetes, or produces the same result as any tested cinnamon preparation.
GINGERDIGESTIVE + MOTILITY RESEARCH
GINGER · ZINGIBER OFFICINALE
05 · Digestive + motility context
Ginger has a long food and traditional-use history and has been studied in several human digestive contexts. A small trial in functional dyspepsia examined gastric emptying using a specific ginger preparation.
Evidence boundary A small ingredient study does not prove that Burn treats reflux, constipation, gastroparesis, nausea, or a microbiome disorder.
FROM MECHANISM TO REAL LIFE
Four layers that should never be collapsed.
Cell mechanism
What happens in a molecular pathway under controlled conditions.
Ingredient research
What a specific standardized substance has been studied to do.
Finished formula
What the complete marketed product can responsibly claim at its actual dose.
Individual outcome
What happens in a real person alongside health history, habits, medicines, and care.
TURN INFORMATION INTO A NEXT STEP
Explore your own
daily pattern.
The Metabolic Rhythm Assessment helps you think through energy, meals, consistency, and expectations without diagnosing a condition.
START THE ASSESSMENT →